Showing results (31-40 of 51) with videos related to
Sort By:
Pageof 6
The Journal of Infectious Diseases|March 30, 2012
Interferon α-stimulated natural killer cells from patients with acute hepatitis C virus (HCV) infection recognize HCV-infected and uninfected hepatoma cells via DNAX accessory molecule-1Kerstin A Stegmann, Niklas K Björkström, Sandra Ciesek, et al.Hepatology Communications|May 24, 2021
SOMAscan Proteomics Identifies Serum Biomarkers Associated With Liver Fibrosis in Patients With NASHYi Luo, Samir Wadhawan, Alex Greenfield, et al.Clinical and Translational Gastroenterology|April 3, 2019
Elbasvir/Grazoprevir in People With Hepatitis C Genotype 1 Infection and Child-Pugh Class B Cirrhosis: The C-SALT StudyIra M Jacobson, Fred Poordad, Roberto Firpi-Morell, et al.JHEP Reports : Innovation in Hepatology|March 3, 2023
Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trialElizabeth A Brown, Anne Minnich, Arun J Sanyal, et al.Hepatology (Baltimore, Md.)|October 4, 2021
BMS-986263 in patients with advanced hepatic fibrosis: 36-week results from a randomized, placebo-controlled phase 2 trialEric J Lawitz, Diane E Shevell, Giridhar S Tirucherai, et al.The Journal of Infectious Diseases|September 9, 2006
Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infectionAna I Romero, Martin Lagging, Johan Westin, et al.Lancet (London, England)|December 18, 2018
Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trialArun Sanyal, Edgar D Charles, Brent A Neuschwander-Tetri, et al.Journal of Extracellular Biology|June 28, 2024
Comparison of different methods for isolating CD8<sup>+</sup> T lymphocyte-derived extracellular vesicles and supramolecular attack particlesAshwin K Jainarayanan, Jesusa Capera, Pablo F Céspedes, et al.International Journal of Molecular Sciences|June 24, 2022
Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and FibrosisTobias Puengel, Sander Lefere, Jana Hundertmark, et al.Scientific Reports|August 19, 2018
An Evaluation of the Collagen Fragments Related to Fibrogenesis and Fibrolysis in Nonalcoholic SteatohepatitisYi Luo, Abdul Oseini, Robert Gagnon, et al.Pageof 6